Cat. #162057
Anti-Tap63 [TAp63-4.1]
Cat. #: 162057
Sub-type: Primary antibody
Target: transactivation domain of tumour protein p63
Class: Monoclonal
Reactivity: Human ; mouse ; rat
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Institute: Moravian Biotechnology
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-Tap63 [TAp63-4.1]
- Clone: TAp63-4.1
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Molecular weight: 76 kD
- Reactivity: Human ; mouse ; rat
- Host: Mouse
- Description: Antibody created to detect the TA isoform of p63 (TAp63) with tumour suppressor role and differentiate from the deltaN (deltaNp63) isoforms of the same protein. Binding specificity: epitope mapping using phage disply identified the epitope LSDPxW for all clones.
- Immunogen: Recombinant human TAp63delta
- Isotype: IgG2a kappa
- Production details: B cell donor: Splenocytes from mouse immunised with recombinant TAp63? , Fusion partner: SP2
Target Details
- Target: transactivation domain of tumour protein p63
- Molecular weight: 76 kD
- Target background: p63 is a transcription factor of the p53 gene family, encoded by the TP63 gene located at chromosome 3q28. p63 exists as N-terminal isoforms that either contain (TAp63) or lack (deltaNp63) the p53-like transactivation domain at the N-terminus. C-terminal isoforms are produced by alternative splicing of 3' exons. TAp63 is involved in germ cell maintenance and myocyte differentiation, and is expressed in some lymphocytes and lymphomas/leukaemias.
- Epitope sequence: LSDPxW sequence of tumour protein p63 (TA isoform)
Handling
- Format: Liquid
References
- Orzol et al. 2016. Tumour Biol. Aug:37(8):10133-40. PMID: 26825981
- Galoczova et al. 2021. Virchows Arch. Apr:478(4):627-636. PMID: 33037932
- Pokorna et al. 2022. Front Oncol. Jul 14:12:924354. PMID: 35912167